431 related articles for article (PubMed ID: 24433495)
1. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dressler D; Kupsch A; Seitzinger A; Paus S
Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
3. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.
Dressler D; Paus S; Seitzinger A; Gebhardt B; Kupsch A
J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):1014-9. PubMed ID: 23687362
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type B for cervical dystonia.
Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
[TBL] [Abstract][Full Text] [Related]
9. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
[TBL] [Abstract][Full Text] [Related]
10. Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data.
Jen MH; Kurth H; Iheanacho I; Dinet J; Gabriel S; Wasiak R; Jost WH
J Med Econ; 2014 Nov; 17(11):803-9. PubMed ID: 25155368
[TBL] [Abstract][Full Text] [Related]
11. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
Samotus O; Lee J; Jog M
J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
Dressler D; Bigalke H
J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
[TBL] [Abstract][Full Text] [Related]
14. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
Pagan FL; Harrison A
Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.
Tarsy D
Mov Disord; 1997 Jan; 12(1):100-2. PubMed ID: 8990061
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
Slawek J; Friedman A; Potulska A; Krystkowiak P; Gervais C; Banach M; Ochudlo S; Budrewicz S; Reclawowicz D; Rynkowski M; Opala G
Funct Neurol; 2007; 22(2):95-100. PubMed ID: 17637212
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Duarte GS; Castelão M; Rodrigues FB; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004314. PubMed ID: 27782297
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
Evidente VG; Fernandez HH; LeDoux MS; Brashear A; Grafe S; Hanschmann A; Comella CL
J Neural Transm (Vienna); 2013 Dec; 120(12):1699-707. PubMed ID: 23779062
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):22-6. PubMed ID: 19959960
[TBL] [Abstract][Full Text] [Related]
20. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
Han Y; Stevens AL; Dashtipour K; Hauser RA; Mari Z
J Neurol; 2016 Apr; 263(4):772-80. PubMed ID: 26914922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
